The biochemistry of blood coagulation has been well defined over the past 50 years. Although much is known about the sequence of the proteolytic cascade and its regulation in the pathway to fibrin generation, many important questions remain unsolved about the mechanism of initiation and the structure of the protein complexes that form during blood coagulation.
Introduction
The biochemistry of the blood coagulation cascade has been carefully studied, and much is known about the sequence of events within the proteolytic cascade and its regulation during the generation of fibrin. However, many important questions remain unsolved, and significant progress in this field continues. Understanding blood coagulation offers opportunities for improved treatment of abnormalities of blood coagulation, including bleeding disorders and thrombosis.
Synthesis of blood coagulation proteins
The protein pro-cofactors in blood coagulation are unusually large, and their site of synthesis and complexity of synthesis have been of considerable interest.
Factor V
In circulating blood, approximately 80% of factor V is in plasma and 20% in platelet granules. Evidence exists for both synthesis of factor V by isolated megakaryocytes and endocytosis of plasma factor V. The contribution of these two processes to the platelet factor V pool has been uncertain. Studies in patients with the factor V Leiden mutation who had received either a liver or a bone marrow transplant from a donor with normal factor V indicated that most of the platelet factor V is of plasma origin. However, concern remained that the Western blot analysis used may not have been sufficiently quantitative to adequately determine the contribution of endogenous synthesis of factor V. In a recent similar study, Christella et al. [1] used kinetic analyses of activated protein C inactivation of factor Va to determine the source of platelet factor V. Studies of inactivation of factor Va from the platelets and plasma of a patient with the factor V Leiden mutation who had received a bone marrow transplant from a normal donor demonstrated that platelet factor V is primarily derived from plasma. Consistent with clinical observations emphasizing the importance of platelet factor V to hemostasis in humans, Gould et al. [2••] have shown that although platelet factor V is of plasma origin, the factor V stored in platelet granules is physically and functionally distinguishable from that in plasma. Platelet factor V is partially activated in the granules, is differentially posttranslationally modified relative to plasma factor V, and platelet factor Va is resistant to inactivation by activated protein C relative to plasma factor Va.
In contrast to the evidence for plasma as the origin of platelet factor V in humans, mouse platelet factor V seems to be generated primarily by biosynthesis in the megakaryocyte [3] . Mice deficient in megakaryocyte/platelet factor V synthesis were generated by transplanting fetal liver cells from factor V-null mice into irradiated wildtype mice. In mice that had undergone transplantation, total factor V levels were mildly decreased, but platelet factor V was less than 1% in comparison with wild-type mice transplanted with wild-type fetal liver cells. Mice lacking platelet factor V did not experience spontaneous hemorrhage or bleeding after mild trauma. Similarly, transgenic mice can be generated that express only plasma factor V or platelet factor V [4]. The transgenic mice have relatively normal tail bleeding times. These results identify a significant difference between mouse and human platelets and emphasize the need for caution in the application of data from animal models to human systems.
Factor VIII
Although significant effort has been invested in developing gene therapy for hemophilia A, this approach is not yet available, and patients are treated with replacement therapy. The expression of factor VIII in heterologous systems is several orders of magnitude lower than that of other proteins of similar size. Thus, interest remains high in improving the production of factor VIII, both for replacement therapy and to improve the prospects for gene therapy. Unstable mRNA, interaction with protein chaperones in the endoplasmic reticulum, and the need for facilitated transport from the endoplasmic reticulum to the Golgi apparatus all limit factor VIII expression. B domain-deleted factor VIII is expressed more efficiently than full-length factor VIII because of higher mRNA levels. A targeted point mutation in the A1 domain reduces interaction with an endoplasmic reticulum chaperone protein. Replacement of the full-length B domain with a truncated 226 amino acid B domain sequence, including 6 asparagine-linked oligosaccharide binding sites to improve endoplasmic reticulum to Golgi apparatus transport through interaction with LMAN1 and inclusion of the A1 domain point mutation, provided a factor VIII variant with full activity that was secreted 15to 25-fold more efficiently both in vitro and in vivo [5] . Recombinant porcine factor VIII is more efficiently expressed than recombinant human factor VIII. Using homolog-scanning mutagenesis, Doering et al. [6] have shown that the A1 and activation peptide-A3 domains of porcine factor VIII confer high-level expression of a human/porcine chimera. It appears that the major difference in expression level occurs during passage of the protein through the endoplasmic reticulum and the Golgi apparatus. By extending this strategy, point mutations in the A1 and activation peptide-A3 domains may be identified that could be combined with the strategy of Miao et al.
[5] to further improve production of recombinant factor VIII.
In a novel approach to gene therapy for hemophilia A, Yarovoi et al. [7] have generated a transgenic mouse line that expresses human factor VIII ectopically in megakaryocytes. Human factor VIII, at levels of 3 to 9% of normal mouse plasma levels, was stored in the granules of platelets, but no human factor VIII was detected in plasma. The transgenic mice were crossed with factor VIII-null mice to generate mice that had factor VIII only in platelet granules. The factor VIII present in platelet granules was able to partially correct a whole blood clotting time and a cuticle bleeding time, but in a FeCl 3 model of carotid artery thrombosis, occlusion occurred consistent with factor VIII levels of 50 to 100%.
Combined deficiency of factor V and factor VIII
Combined factor V-factor VIII deficiency has previously been shown to be associated with a defect in LMAN1 (also known as endoplasmic reticulum intermediate Golgi compartment-53 [ERGIC-53]), a protein necessary for the secretion of some proteins. However, a defect in LMAN1 did not account for combined factor V-factor VIII deficiency in all affected individuals. Ginsburg et al. [8••] have now shown that mutations in a second ERGIC protein, multiple coagulation factor deficiency 2 (MCFD2), are also associated with the combined deficiency. MCFD2 is found in the ERGIC in a calcium-dependent association with LMAN1, suggesting that this protein complex serves as a specific cargo receptor for the transport of some proteins from the endoplasmic reticulum to the Golgi apparatus.
Initiation of blood coagulation: tissue factor and microparticles
Although considerable information is available that describes the blood coagulation pathways, the issue of the initiation of blood coagulation remains perplexing. Although a role for the contact phase contributing to in vivo blood coagulation has been long put to rest, the classic role of tissue factor has also been challenged. The traditional model of blood coagulation postulates that blood clotting is initiated via tissue factor; that tissue factor is not exposed to blood but is constitutively expressed on cells separated from flowing blood; that upon vascular injury, tissue factor comes in contact with flowing blood, initiating reactions that lead to the generation of fibrin and a fibrin clot. Although these features may be characteristics of the primary mechanism of hemostasis, thrombosis may occur via a separate pathway. Tissue factor circulates in blood at levels of approximately 100 to 150 pg/ml. Whether this tissue factor is functional is hotly debated. Circulating human tissue factor antigen integrates into thrombi formed on pig arterial media or collagen-coated glass slides exposed to flowing human blood in vitro. The observation of intravascular tissue factor, albeit at minute concentration, and the observation that this tissue factor accumulates in the growing thrombus has required reconsideration of the mechanisms involved in fibrin formation.
Advances in intravital microscopy have contributed to the ability to observe thrombus formation in real time in a living animal. Falati et al. [9•] described a system that allows for the nearly simultaneous high-speed collection of microscopic images from three fluorescence channels and one bright-field channel during laser-induced vessel wall injury of arterioles in the microcirculation. Platelets, tissue factor, and fibrin were observed in real time to accumulate within the developing thrombus over a rapid time course. In a separate study, Falati et al. [10••] determined that the accumulation of tissue factor and the generation of fibrin were dependent on the presence of P-selectin and PSGL-1. In mice lacking either of these vascular adhesion molecules, minimal tissue factor or fibrin was present in the thrombus. The authors postulated that microparticles bearing both tissue factor and PSGL-1 circulate in the blood and accumulate in the platelet thrombus via the interaction of platelet P-selectin and microparticle PSGL1. Concentration of tissue factor initiates blood coagulation and fibrin formation.
Although intravascular tissue factor has been previously described, this tissue factor has been suggested to be associated with various compartments. Muller et al. [11] have suggested that plasma tissue factor is present on circulating platelet-derived microparticles, Falati et al.
[10••] have shown tissue factor to be associated with leukocyte-derived microparticles, and Bogdanov et al. [12] have claimed that tissue factor is associated with both microparticles and free in plasma. Both Muller et al. [11] and Camera et al. [13] have identified tissue factor within unstimulated platelets by immunomicroscopy, and this tissue factor can be expressed on the membrane surface with platelet agonists upon platelet activation. This important area of investigation will likely require further careful experimentation to determine the source of intravascular tissue factor, its activation state, and its role in the initiation of blood coagulation.
Bogdanov et al. [12] have described an alternatively spliced form of human tissue factor that circulates in the blood. This species contains most of the extracellular domain and lacks a transmembrane domain characteristic of tissue factor, but instead has a unique peptide sequence at the C terminus because of a frame shift associated with the absence of Exon 5. Because Exon 5 encodes a region that is required for factor VIIa binding, the claim of full procoagulant activity for this species requires confirmation. Nonetheless, the authors suggest that this form of tissue factor contributes to thrombus growth. Further definition of the functional properties of this species will require heterologous expression and functional characterization of the isolated protein.
The mode of generation of microparticles remains unknown. Specifically, it is unclear whether microparticles are constitutively generated by blood cells; whether their generation is regulated, as during an inflammatory response or tissue injury; or whether apoptosis leads to microparticle generation. Hrachovinova et al. [14•] have shown that P-selectin and PSGL-1 play a role in microparticle generation because the number of microparticles in circulating blood is reduced in a mouse lacking PSGL-1. These procoagulant microparticles are able to reduce the prolonged bleeding time in a mouse lacking factor VIII. The role of microparticles in blood coagulation, specifically in tissue factor-mediated initiation and fibrin propagation, is a promising and fertile area for future investigation.
Protein structure
The blood coagulation proteins assemble on membrane surfaces to form large macromolecular complexes. The structure of these complexes has been of great interest.
␥-Carboxyglutamic acid-rich domains of vitamin K-dependent proteins
Vitamin K-dependent proteins of blood coagulation contain a conserved ␥-carboxyglutamic acid-rich domain (Gla domain) at their N termini. The Gla domains of vitamin K-dependent proteins play a critical role in blood coagulation, providing the phospholipid binding site for the assembly of vitamin K-dependent enzymes and substrates with protein cofactors on a membrane surface. Although many models have been proposed for the mode of Gla domain binding to phospholipid, Huang et al. [15••] have provided the first structural data. The structure of prothrombin fragment 1, the Gla domain and first kringle domain of prothrombin, bound to lysophosphatidylserine and calcium ions, was determined using X-ray crystallography and nuclear magnetic resonance spectroscopy. The serine head group of the phospholipid binds Gla domain bound calcium ions 5 and 6 and Gla residues 17 and 21, fixed elements of the Gla domain fold. This suggests the structural basis of phosphatidylserine specificity among Gla domains. Nevertheless, the binding affinities of the vitamin K-dependent proteins of blood coagulation for phospholipid vary quite markedly. Although the folds of the Gla domains are quite similar, small alterations in structure, caused for example by differences in calcium ion liganding between factor IX and other vitamin-dependent proteins, likely influence phospholipid binding [16, 17] . Another feature of Gla domain binding of phospholipid is insertion of the amino terminal -loop into the lipid bilayer. Although the peptide backbone structures of the -loops of Gla domains are similar, critical amino acid sequence variation influences the fine structure of this region [16] . Shikamoto et al. [17] have demonstrated that the structure of a complex of the factor IX Gla domain bound to factor IX-binding protein exhibits subtle structural differences when liganded with calcium ions alone or with calcium and magnesium ions. Magnesium ions in the presence of calcium ions appear to modulate the activation of factor IX by factor VIIa/tissue factor and the activation of factor X by factor IXa and factor VIII. Magnesium ions replace calcium ions 1, 7, and 8 in the factor IX Gla domain-factor IX binding protein complex. However, magnesium ions alone are not sufficient to organize the folding of Gla domains into their phospholipid binding conformation. Wang et al. [18] have obtained the first complete Gla domain structure in the presence of magnesium ions. In the Gla domain of factor X in the presence of magnesium ions, the first 11 residues assume a novel conformation, likely representing a folding intermediate between the unliganded and calcium-liganded Gla domain.
Protein-protein Interactions
A prominent feature of the proteins involved in the blood coagulation cascade is the high degree of specificity that enzymes have for protein substrates and their protein cofactors, the requirement for protein cofactors, and the assembly of these protein complexes on membrane surfaces.
Tenase complex (factor IXa-factor VIIIa)
Activated factor IX (factor IXa) forms a complex with activated factor VIII (factor VIIIa) that assembles on a phospholipid membrane to catalyze the conversion of factor X to factor Xa in the presence of Ca +2 . Multiple contact sites have been suggested between different regions of these proteins. A site of interaction between factor IXa and factor VIIIa occurs between the C terminal portion of the Gla domain of factor IX and the light chain of factor VIIIa [19•]. Using three synthetic peptide analogs of the Gla domain of factor IX, Phe 25 was shown to crosslink to the light chain of factor VIIIa. By studying the interaction between factor IXa and low-density lipoprotein receptor-related protein, another important site of interaction between factor IXa and factor VIIIa was identified as the surface region Phe 342-Asn 346 of the protease domain of factor IXa binding to the A2 domain of factor VIIIa [20].
Prothrombinase complex (factor Xa-factor Va)
The prothrombinase complex consists of the assembly of factor Xa and factor Va in the presence of Ca +2 on a negatively charged phospholipid membrane. This complex converts prothrombin to thrombin. Exosite-dependent substrate recognition may represent an important mechanism underlying the function of trypsin-like enzymes of coagulation [21] . Extensive interactions between the factor Xa/factor Va complex and regions of prothrombin distant from the sessile bonds drive substrate affinity and enforce substrate specificity of this enzyme complex [21] . Inhibition studies of prothrombinase using peptides derived from prothrombin and factor X have shown that the region on factor Xa, from Val 415 to Arg 429, is directly involved with prothrombin recognition and that the area on prothrombin, from Tyr 557 to Gln 571, could be a site for factor Xa binding. There is inhibition of the complex by the peptide representing factor Xa, from Ala 404 to Phe 418, in a mechanism that is factor Va dependent. This could be part of an extended factor Va-binding site on factor Xa [22] . Study of the inhibition of thrombin generation by sphingolipids showed that the interactions between factor Va and the Gla domain of factor Xa are disrupted by sphingosine 1-phosphate, whereas the Gla domain of prothrombin is not necessary for the sphingosine 1-phosphate inhibitory effect [23] . By constructing chimeras in which the Gla domain and the first epidermal growth factor domain of factor X were separately substituted by the corresponding domains in factor IX, it was shown that in the prothrombinase complex, the Gla and first epidermal growth factor domain of factor X are not directly involved in the factor Va-factor Xa interaction. Also, the first epidermal growth factor and Gla domains of factor X play a direct role in the complex formed with tissue factor and factor VIIIa [24] . The basic residues of proexosite 1 on prothrombin are factor Va-dependent recognition sites for the prothrombinase complex, interacting with the C terminal region of the heavy chain of factor Va [25] . Three amino acid residues (Tyr 324, Glu 330, and Val 331) from the factor Va heavy chain are important for the high-affinity interaction for factor Va with factor Xa on the membrane surface, specifically with regard to the expression of factor Va cofactor activity [8••,26] . Furthermore, Asp 695-Tyr 698 of the heavy chain of factor Va are important not only for cofactor activity but also for cleavage of factor V by thrombin at Arg 709 [27] .
Regulation of the cascade
Assembly of the tissue factor-factor VIIa complex mediates presentation of the substrates, factors X and IX, by remote exosite loci on both tissue factor and factor VIIa [28•]. Recombinant nematode anticoagulant protein c2 is an inhibitor of thrombin formation, acting at the tissue factor-factor VIIa level. Its mechanism requires binding to circulating factor X or factor Xa to form a binary complex that then forms a final quaternary complex with tissue factor-factor VIIa similar to that of tissue factor pathway inhibitor. However, unlike the factor Xa/tissue factor pathway inhibitor inhibition of tissue factor/factor VIIa, this complex forms a complex with an unobstructed catalytic site [29] .
A peptide derived from a plant, thionin, is able to stimulate prothrombinase activity. The peptide facilitates the formation of the factor Va, factor Xa, and prothrombin complex and is able to substitute for factor Va as a cofactor [30] . Based on an exosite peptide inhibitor of factor VIIa, and using a substrate phage display approach, an inhibitory 27-mer peptide was obtained. It has a high degree of specificity and potency because of its tight exosite interactions with factor VIIa and complete (∼99%) inhibition of factor X activation caused by steric hindrance in the substrate binding cleft of the active site of factor VIIa [31•].
Disruption of the assembly of the tenase and prothrombinase complex on phospholipid membranes is a potential therapeutic strategy for inhibiting blood coagulation. Lactadherin is an efficient inhibitor of the tenase complex by competing with factor VIII for membrane binding sites. It does so in a manner that is more potent than inhibition of the prothrombinase complex, inhibiting factor V binding to phospholipid membranes, but to a lesser degree [32•]. Inhibition of the tenase complex by low molecular weight heparin occurs by virtue of its binding to an exosite on factor IXa, thus antagonizing the cofactor activity of factor VIIIa without disrupting factor IXafactor VIIIa assembly [33] .
Conclusion
Significant progress continues to be made in understanding the details of the blood coagulation cascade. Future directions will likely focus on the structural biology of the protein complexes that form during blood coagulation as well as understanding the blood coagulation cascade within its physiologic and pathologic context by the analysis of this system in living animals. • 28 Huang H, Norledge BV, Liu C, et al.: Selective attenuation of the extrinsic limb of the tissue factor-driven coagulation protease cascade by occupancy of a novel peptidyl docking site on tissue factor. Biochemistry 2003, 42:10619-10626. This paper uses phage display to identify a peptide that specifically binds a functional extracellular domain of tissue factor and selectively inhibits FXa generation without inhibiting FIX activation. It is a novel interesting concept modulating the coagulation cascade at a very early point.
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